Karyopharm Therapeutics (KPTI)
Commercializer of the XPO1 inhibitor selinexor for blood cancers.
Something off on this page? Send us feedback.
Commercializes selinexor as XPOVIO in the United States and licenses NEXPOVIO/XPOVIO abroad, earning product and partner revenue. The business is concentrated in one approved molecule and additional selinexor indications.
Develops and commercializes selinexor, an oral XPO1 inhibitor sold as XPOVIO in the United States and NEXPOVIO in parts of Europe and the United Kingdom. U.S. sales cover labeled multiple-myeloma and diffuse large B-cell lymphoma settings, supported by an oncology field team and reimbursement assistance.
Licenses ex-U.S. development and commercialization to Menarini, Antengene, Neopharm and FORUS, generating partner revenue through royalties, milestones and reimbursements. The pipeline also concentrates on selinexor, with late-stage work in myelofibrosis and multiple myeloma plus earlier eltanexor development.
Relies on a single approved molecule, partner execution abroad, regulatory pathways for new indications, and continuing access to financing.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | H.C. Wainwright | Downgrade | Buy | Neutral | $13 | $3 |
| Jul 31, 2026 | Robert W. Baird | Target | $21 | $3 | ||
| Jul 31, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral | ||
| Jul 21, 2026 | RBC Capital | Reiterate | Outperform | $19 | $16 | |
| May 6, 2026 | H.C. Wainwright | Target | $15 | $13 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $65.1M · Total debt $215.9M · Total assets $111.3M · Shareholders' equity −$330.2M
- Revenue
- $33.4M
- Operating income
- −$22.5M
- Net income
- −$67.0M
No dividends on record.
| Institutions100 holders · as of Mar 31, 2026 · largest filers plus last quarter's tail | ≈ 77.52% | 17.58M shares | |
| Insiders14 holders · as of Sep 2, 2026 | 3.77% | 855.5K shares | |
| Otherremainder | ≈ 18.71% | 4.24M shares |
22.68M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Commodore Capital LPInstitution | 8.60% | 1.95M | 13Fas of Mar 31, 2026 |
Ra Capital Management, L.P.Institution | 8.45% | 1.92M | 13Fas of Mar 31, 2026 |
Adage Capital Management, L.P.Institution | 8.03% | 1.82M | 13Gfiled May 13, 2026 ↗ |
Adage Capital Partners GP, L.L.C.Institution | 7.96% | 1.81M | 13Fas of Mar 31, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 6.80% | 1.54M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 1, 2026 | Kristin Abate | officer: Chief Accounting Officer | −19 | $2.02 |
| Jul 28, 2026 | Stuart Poulton | officer: EVP, Chief Development Officer | −189 | $7.10 |
| May 14, 2026 | Michael Mano | officer: EVP, CLO&Secretary | −266 | $9.50 |
| May 14, 2026 | Richard A. Paulson | director, officer: President and CEO | −2,203 | $9.50 |
| May 14, 2026 | Kristin Abate | officer: Chief Accounting Officer | −53 | $9.50 |
- Bristol-Myers Squibb
Broad late-line multiple-myeloma and DLBCL portfolio.
- Johnson & Johnson
Large multiple-myeloma franchise across treatment sequencing.
- Pfizer
Bispecific and JAK-inhibitor options in two core blood cancers.
- GSK (ADR)
BCMA and JAK-inhibitor therapies span two key battlefields.
- Incyte
Foundation myelofibrosis therapy and a competing add-on pipeline.
- Sanofi (ADR)
Sarclisa regimens compete in relapsed multiple myeloma.
- Gilead Sciences
CAR-T alternative in relapsed or refractory DLBCL.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics | $1.80 | +1.12% | $40.6M | — | — | 0.3 | −11.9% |
| Bristol-Myers Squibb | $67.50 | −0.23% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Johnson & Johnson | $275.43 | +0.07% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Pfizer | $28.99 | −0.14% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| GSK (ADR) | $50.89 | +0.92% | $101.06B | 15.8 | 9.1 | 2.2 | +2.7% |
| Incyte | $129.60 | +0.61% | $26.11B | 16.4 | 53.4 | 4.5 | +37.7% |
| Sanofi (ADR) | $44.76 | +0.66% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Gilead Sciences | $148.70 | −0.61% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| Median | 24.2 | 13.5 | 2.8 | +6.6% |